International Journal of Colorectal Disease

, Volume 29, Issue 6, pp 663–671 | Cite as

Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma

  • Enken Drecoll
  • Ulrich Nitsche
  • Karina Bauer
  • Sabina Berezowska
  • Julia Slotta-Huspenina
  • Robert Rosenberg
  • Rupert Langer
Original Article
First Online:
Accepted:

Abstract

Purpose

The molecular chaperone heat shock protein 90 (HSP90) plays an important role in several types of tumors also participating in the modulation of the activity of receptor tyrosine kinases activity such as members of the Her family. We evaluated the significance of HSP90 and Her2 expression in colon cancer.

Methods

HSP90 and Her2 expression was determined by immunohistochemistry and by fluorescence in situ hybridization (FISH) on 355 primary resected colon carcinomas. Results were correlated with pathologic features (Union for International Cancer Control (UICC) pTNM category, tumor localisation, tumor differentiation), additional molecular genetic characteristics (BRAF, KRAS mutational status, mismatch repair genes (MMR)), and survival.

Results

HSP90 immunoreactivity was observed in various degrees. Fifty-one cases (14 %) were positive for Her2 (score 2+ and 3+) with 16/43 cases with Her2 2+ staining pattern showing amplification of Her2 determined by FISH. There was a significant correlation between high HSP90 expression and Her2 overexpression (p = 0.011). High HSP90 expression was associated with earlier tumor stages (p = 0.019), absence of lymph node (p = 0.006), and absence of distant metastases (p = 0.001). Patients with high tumoral HSP90 levels had a better survival (p = 0.032), but this was not independent from other prognostic relevant pathologic parameters. Her2 expression was not associated with any of the investigated histopathological, molecular, or clinical parameters.

Conclusions

High HSP90 levels are reflecting lower malignant potential in colon cancer. Her2 positivity can be observed in a small number of cases. Targeting HSP90 and/or Her2 may be an alternative therapeutic approach in colon cancer in a subset of patients.

Keywords

HSP90 Her2 Immunohistochemistry Colon cancer 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors thank Mrs. Melitta Winkler, Mrs. Ruth Wichnalek, and Mrs. Caroline Hammer for their expert technical assistance. Rupert Langer received financial support by the Deutsche Forschungsgemeinschaft (DFG), grant number LA2706/1-1.

References

  1. 1.
    Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J Cancer 3:137–144. doi: 10.7150/jca.4090 PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, Wei W, Xua WP (2013) Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. doi: 10.1016/j.arcmed.2013.07.001 Google Scholar
  3. 3.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. doi: 10.1016/S0140-6736(10)61121-X PubMedCrossRefGoogle Scholar
  4. 4.
    Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, Jimenez U, Alonso V, Garcia-Carbonero R, Sastre J, Colomer R, Cortes-Funes H, Jimeno A (2011) Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 13(3):179–184. doi: 10.1007/s12094-011-0637-6 PubMedCrossRefGoogle Scholar
  5. 5.
    Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR (2010) Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 41(11):1577–1585. doi: 10.1016/j.humpath.2010.02.018 PubMedCrossRefGoogle Scholar
  6. 6.
    Baiocchi G, Lopes A, Coudry R, Rossi B, Soares F, Aguiar S, Guimarães G, Ferreira F, Nakagawa W (2009) ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 24(9):1059–1068. doi: 10.1007/s00384-009-0702-6 PubMedCrossRefGoogle Scholar
  7. 7.
    Li Q, Wang D, Li J, Chen P (2011) Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 11(1):277PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    McKay J, Loane J, Ross V, Ameyaw M, Murray G, Cassidy J, McLeod H (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 86:568–573PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Park D, Kang M, Oh S, Kim H, Cho Y, Sohn C, Jeon W, Kim B, Han W, Kim H, Ryu S, Sepulveda A (2007) HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 22:491–497PubMedCrossRefGoogle Scholar
  10. 10.
    Kavanagh D, Chambers G, O’Grady L, Barry K, Waldron R, Bennani F, Eustace P, Tobbia I (2009) Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9:1–6PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F (2006) Her-2/neu protein expression in colorectal cancer. BMC Cancer 6:123PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Herreros-Villanueva M, Rodrigo M, Claver M, Muñiz P, Lastra E, García-Girón C, Coma del Corral M (2011) KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 38(2):1315–1320. doi: 10.1007/s11033-010-0232-x PubMedCrossRefGoogle Scholar
  13. 13.
    Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E (2008) A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283(4):2031–2041. doi: 10.1074/jbc.M701803200 PubMedCrossRefGoogle Scholar
  14. 14.
    Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S, Yarden Y (2006) Hsp90 recognizes a common surface on client kinases. J Biol Chem 281(20):14361–14369. doi: 10.1074/jbc.M512613200 PubMedCrossRefGoogle Scholar
  15. 15.
    Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6(3):1123–1132. doi: 10.1158/1535-7163.MCT-06-0628 PubMedCrossRefGoogle Scholar
  16. 16.
    Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18(1):64–76. doi: 10.1158/1078-0432.ccr-11-1000 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Kubota H, Yamamoto S, Itoh E, Abe Y, Nakamura A, Izumi Y, Okada H, Iida M, Nanjo H, Itoh H, Yamamoto Y (2010) Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperon 15(6):1003–1011. doi: 10.1007/s12192-010-0211-0 CrossRefGoogle Scholar
  18. 18.
    Chen W-S, Lee C-C, Hsu Y-M, Chen C-C, Huang T-S (2011) Identification of heat shock protein 90α as an IMH-2 epitope-associated protein and correlation of its mRNA overexpression with colorectal cancer metastasis and poor prognosis. Int J Colorectal Dis 26(8):1009–1017. doi: 10.1007/s00384-011-1200-1 PubMedCrossRefGoogle Scholar
  19. 19.
    Bauer K, Nitsche U, Slotta-Huspenina J, Drecoll E, von Weyhern CH, Rosenberg R, Hofler H, Langer R (2012) High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer. Cell Oncol (Dordr) 35(3):197–205. doi: 10.1007/s13402-012-0079-3 CrossRefGoogle Scholar
  20. 20.
    Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637–650. doi: 10.1038/modpathol.2011.198 PubMedCrossRefGoogle Scholar
  21. 21.
    Müller A, Giuffre G, Edmonston TB, Mathiak M, Roggendorf B, Heinmöller E, Brodegger T, Tuccari G, Mangold E, Buettner R, Rüschoff J (2004) Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Molec Diagn 6(4):308–315. doi: 10.1016/S1525-1578(10)60526-0 CrossRefGoogle Scholar
  22. 22.
    Rauser S, Weis R, Braselmann H, Feith M, Stein HJ, Langer R, Hutzler P, Hausmann M, Lassmann S, Siewert JR, Hofler H, Werner M, Walch A (2007) Significance of HER2 low-level copy gain in Barrett’s cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 13(17):5115–5123. doi: 10.1158/1078-0432.CCR-07-0465 PubMedCrossRefGoogle Scholar
  23. 23.
    Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Hofler H, Langer R (2012) Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol. doi: 10.1016/j.humpath.2012.08.005 PubMedGoogle Scholar
  24. 24.
    Sobin L, Gospodarowicz ML, Wittekind C (2010) TNM classification of malignant tumors. Wiley, New YorkGoogle Scholar
  25. 25.
    Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumours of the digestive system, 4th edn. Lyon, World Health OrganizationGoogle Scholar
  26. 26.
    Conradi LC, Styczen H, Sprenger T, Wolff HA, Rodel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Rüschoff J, Liersch T (2013) Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol 37(4):522–531. doi: 10.1097/PAS.0b013e318272ff4d PubMedCrossRefGoogle Scholar
  27. 27.
    Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Capelli S, Silini EM, Ardizzoni A (2011) Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104(9):1372–1376PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Suda H, Takayama T (2013) Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol 8(1):191. doi: 10.1186/1746-1596-8-191 PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, Rocken C (2012) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. doi: 10.1093/annonc/mds528 PubMedCentralPubMedGoogle Scholar
  30. 30.
    Ilyas M, Grabsch H, Ellis IO, Womack C, Brown R, Berney D, Fennell D, Salto-Tellez M, Jenkins M, Landberg G, Byers R, Treanor D, Harrison D, Green AR, Ball G, Hamilton P (2013) Guidelines and considerations for conducting experiments using tissue microarrays. Histopathol 62(6):827–839. doi: 10.1111/his.12118 CrossRefGoogle Scholar
  31. 31.
    Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31(3):164–172PubMedCrossRefGoogle Scholar
  32. 32.
    Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10(2):86–103PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Porter JR, Fritz CC, Depew KM (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14(3):412–420. doi: 10.1016/j.cbpa.2010.03.019 PubMedCrossRefGoogle Scholar
  34. 34.
    Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R (2013) Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 39(4):375–387. doi: 10.1016/j.ctrv.2012.10.001 PubMedCrossRefGoogle Scholar
  35. 35.
    Saturno G, Valenti M, De Haven BA, Thomas GV, Eccles S, Clarke PA, Workman P (2013) Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget 4(8):1185–1198PubMedCentralPubMedGoogle Scholar
  36. 36.
    Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther 6(11):2868–2878. doi: 10.1158/1535-7163.mct-07-0410 PubMedCrossRefGoogle Scholar
  37. 37.
    Berezowska S, Novotny A, Bauer K, Feuchtinger A, Slotta-Huspenina J, Becker K, Langer R, Walch A (2013) Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PLoS One 8(7):e69098. doi: 10.1371/journal.pone.0069098 PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y (2012) Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 103(2):342–349. doi: 10.1111/j.1349-7006.2011.02144.x PubMedCrossRefGoogle Scholar
  39. 39.
    Patel HJ, Modi S, Chiosis G, Taldone T (2011) Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov 6(5):559–587. doi: 10.1517/17460441.2011.563296 PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823(3):742–755. doi: 10.1016/j.bbamcr.2011.10.008 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Enken Drecoll
    • 1
  • Ulrich Nitsche
    • 2
  • Karina Bauer
    • 1
  • Sabina Berezowska
    • 3
  • Julia Slotta-Huspenina
    • 1
  • Robert Rosenberg
    • 2
    • 4
  • Rupert Langer
    • 3
  1. 1.Institute of PathologyTechnische Universität MünchenMunichGermany
  2. 2.Department of Surgery, Klinikum Rechts der IsarTechnische Universität MünchenMunichGermany
  3. 3.Institute of PathologyUniversity of BernBernSwitzerland
  4. 4.Department of SurgeryKantonsspital BadenBadenSwitzerland

Personalised recommendations